eyelash growth

OXiGENE, inc., (Nasdaq:OXGN)

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company’s major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

OXiGENE,a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

The Company reported consolidated net income for the three month period ended June 30, 2010 of $2.5 million compared to a consolidated net loss of $8.0 million for the same three month period of 2009. The difference in results for the comparable three month periods was due to an increase in the non-cash gain resulting from a change in fair value of warrants and other financial instruments of $7.3 million and a reduction in total costs and expenses of $3.2 million from $8.2 million in the 2009 period to $5.0 million in the 2010 period. due to the nature of the Company’s warrants and other financial instruments, the instruments are recorded as liabilities on the Company’s Consolidated Balance Sheets. These instruments are adjusted to their fair market value at each reporting period and the difference is recorded as a non-cash gain or loss in the Company’s Consolidated Statements of Operations. The reduction in operating costs and expenses for the comparable three month period is primarily attributable to reductions in a number of clinical program and support costs associated with the restructuring plan implemented in the first quarter of 2010. The operating costs for the 2009 period include costs and expenses of Symphony ViDA, Inc. in July 2009, the Company acquired the equity of Symphony ViDA, Inc. and the entity was merged directly into OXiGENE.

The Company reported a consolidated net loss for the six month period ended June 30, 2010 of $8.5 million compared to a consolidated net loss of $14.5 million for the same six month period of 2009. The difference in results for the comparable six month periods was due to a reduction in total costs and expenses of $3.4 million from $14.8 million in the 2009 period to $11.4 million in the 2010 period and an increase in the non-cash gain resulting from a change in fair value of warrants and other financial instruments of $2.7 million. The reduction in operating costs and expenses for the comparable six month period is primarily attributable reductions in a number of clinical program and support costs associated with the restructuring plan implemented in the first quarter of 2010, with the major impact of this restructuring plan taking effect in the Company’s second quarter of 2010. Operating expenses for the six months of 2010 were also impacted by a $0.5 million one-time restructuring charge.

The Company reported net income attributed to OXiGENE for the second quarter of 2010 of $2.5 million, or $0.04 per share, compared with a net loss attributed to OXiGENE of $5.3 million, or $0.11 per share, for the same period in 2009.

For the six-month period ended June 30, 2010, the net loss attributed to OXiGENE was $8.5 million, or $0.13 per share, compared to a net loss attributed to OXiGENE of $10.8 million, or $0.24 per share, for the comparable period in 2009.

At June 30, 2010, OXiGENE had cash, cash equivalents and restricted cash of approximately $7.3 million compared with approximately $14.1 million at December 31, 2009.

__________________________

CROWN EQUITY HLD (OTC BB: CRWE.OB)

Crown Equity Holdings is a professional consulting firm that assists foreign and domestic companies in all aspects of business development including becoming publicly traded. The company’s IR/PR division has grown into a full online public awareness service firm with a complete line of advertising and marketing tools at their disposal.

LAS VEGAS, Aug. 6, 2010 (GLOBE NEWSWIRE) — Crown Equity Holdings, inc. (the “Company”) (OTCBB:CRWE – News) is pleased to report its financial information for the 6-month period ending June 30, 2010. Revenue for the six months totaled $678,988, compared to $84,357 during the same period in 2009. The Company incurred an operating loss of $26,739 for the six months ending June 30, 2010, compared to an operating loss of $245,796 during the same period in 2009. The Company incurred a net loss of $201,658 for the six months ending June 30, 2010, compared to a net loss of $255,006 for the same period in 2009. The net loss in 2010 was due primarily to an unrealized loss of $169,195 on securities held by the Company.

“We are pleased with the continued progress during the last six months compared to the same period in the previous year,” commented Kenneth Bosket, President and CEO of Crown Equity Holdings, Inc. “Not only do our financial results show strong growth during this year, but we continue to build our internal structure to support future growth,” stated Bosket.

Crown Equity Holdings, Inc. has increased its workforce to an amount of 35, compared to this time last year’s head count of 6, which is a 580% personnel increase. this is in addition to the 10 contractors we recently hired in Pakistan.

(Source: CLICK HERE)

__________________________

Somaxon Pharmaceuticals, inc. (Nasdaq: SOMX)

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. our lead product candidate, Silenor, is approved for the treatment of insomnia characterized by difficulty with sleep maintenance.

Somaxon Pharmaceuticals, inc. (Nasdaq: SOMX) reported today that Somaxon and Procter & Gamble (NYSE: PG) have entered into a co-promotion agreement for Silenor® (doxepin), a newly-approved treatment for insomnia characterized by difficulty with sleep maintenance.

Under the terms of the agreement, Somaxon and Procter & Gamble will co-promote Silenor with a combined 215 sales representatives in the U.S. market. Procter & Gamble’s professional health care sales force will promote Silenor to targeted primary care and other high-prescribing physicians. Somaxon’s focus will be on specialists and other top-decile physicians who treat insomnia. in addition, Procter & Gamble will promote Silenor to targeted pharmacies and will provide supplemental managed care support services for Silenor. Somaxon has also granted Procter & Gamble a right of first negotiation relating to rights to develop and market Silenor as an over-the-counter medication in the U.S.

*******************************************Sign-Up for Free Stock Alerts At http://crwepicks.com/signup*******************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

*******************************************

OXGN, CRWE.OB, & SOMX: OXiGENE Reports Second Quarter 2010 Financial Results